Evidence map›Paper›PMID 33941111›Full record

ArticleBMC cancer2021

Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring.

Yoo Young Dominique Lee, Doan Trang Nguyen, Trevor Moodie, Ricky O'Brien, Anne McMaster, Andrew Hickey, Nicole Pritchard, Per Poulsen, Elizaveta Mitkina Tabaksblat, Britta Weber and 8 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02984566 (LARK), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02984566 naactive not recruitingnot on this map

LARK: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

TypeinterventionalSponsorUniversity of SydneyRan2020 to 2026Enrolled32ConditionsLiver CancerArmsKilovoltage Intrafraction Monitoring
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Yoo Young Dominique LeeDepartment of Radiation Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia. Yooyoung.Lee@health.qld.gov.au.ORCID http://orcid.org/0000-0003-4325-349X
Doan Trang NguyenThe University of Sydney, Sydney, NSW, Australia.
Trevor MoodieDepartment of Radiation Oncology, Crown Princess Mary Cancer Centre, Sydney, NSW, Australia.
Ricky O'BrienACRF Image X Institute, Sydney, NSW, Australia.
Anne McMasterDepartment of Radiation Oncology, Liverpool-Macarthur Cancer Therapy Centre, Sydney, NSW, Australia.
Andrew HickeyDepartment of Radiation Oncology, Crown Princess Mary Cancer Centre, Sydney, NSW, Australia.
Nicole PritchardDepartment of Radiation Oncology, Crown Princess Mary Cancer Centre, Sydney, NSW, Australia.
Per PoulsenDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Elizaveta Mitkina TabaksblatDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Britta WeberDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Esben WormDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
David PryorDepartment of Radiation Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Julie ChuDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Nicholas HardcastleDepartment of Radiation Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Jeremy BoothDepartment of Radiation Oncology, Northern Sydney Cancer Centre, Sydney, NSW, Australia.
Val GebskiUniversity of Sydney NHMRC Clinical Trials Centre, Sydney, NSW, Australia.
Tim WangDepartment of Radiation Oncology, Crown Princess Mary Cancer Centre, Sydney, NSW, Australia.
Paul KeallACRF Image X Institute, Sydney, NSW, Australia.
Aarhus University Hospital · DKCancer Australia · AUThe University of Sydney · AUPrincess Alexandra Hospital · AUPeter MacCallum Cancer Centre · AUUmma University · KEUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStereotactic Ablative Body Radiotherapy (SABR) is a non-invasive treatment which allows delivery of an ablative radiation dose with high accuracy and precision. SABR is an established treatment for both primary and secondary liver malignancies, and technological advances have improved its efficacy and safety. Respiratory motion management to reduce tumour motion and image guidance to achieve targeting accuracy are crucial elements of liver SABR. This phase II multi-institutional TROG 17.03 study, Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring (LARK), aims to investigate and assess the dosimetric impact of the KIM real-time image guidance technology. KIM utilises standard linear accelerator equipment and therefore has the potential to be a widely available real-time image guidance technology for liver SABR.

methodsForty-six patients with either hepatocellular carcinoma or oligometastatic disease to the liver suitable for and treated with SABR using Kilovoltage Intrafraction Monitoring (KIM) guidance will be included in the study. The dosimetric impact will be assessed by quantifying accumulated patient dose distribution with or without the KIM intervention. The patient treatment outcomes of local control, toxicity and quality of life will be measured. DISCUSSION: Liver SABR is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of KIM as a potential solution for real-time image guidance in liver SABR.

trial registrationThis trial was registered on December 7th 2016 on ClinicalTrials.gov under the trial-ID NCT02984566 .

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsOrgan MotionRadiosurgeryRadiotherapy, Image-GuidedAustraliaClinical Trials, Phase II as TopicDenmarkFiducial MarkersHumansMulticenter Studies as TopicQuality of LifeRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedRespirationHepatocellular carcinomaKilovoltage intrafraction monitoringLARK trialLiver CancerOligometastasesStereotactic radiotherapy

Identifiers

PMID33941111
PMCPMC8091536
OpenAlexW3159838841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.